263 related articles for article (PubMed ID: 15914623)
1. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.
Martín AP; de Moraes LV; Tadokoro CE; Commodaro AG; Urrets-Zavalia E; Rabinovich GA; Urrets-Zavalia J; Rizzo LV; Serra HM
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2056-63. PubMed ID: 15914623
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
3. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
6. Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveoretinitis.
Busch M; Bauer D; Hennig M; Wasmuth S; Thanos S; Heiligenhaus A
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):39-46. PubMed ID: 23211816
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin is proinflammatory in experimental autoimmune uveitis.
Hikita ST; Vistica BP; Jones HR; Keswani JR; Watson MM; Ericson VR; Ayoub GS; Gery I; Clegg DO
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4435-43. PubMed ID: 17003437
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
Commodaro AG; Peron JP; Lopes CT; Arslanian C; Belfort R; Rizzo LV; Bueno V
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2568-74. PubMed ID: 20019358
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of experimental autoimmune uveoretinitis induced by interphotoreceptor retinoid-binding protein.
Kawashima H; Fujiño Y; Mochizuki M
Jpn J Ophthalmol; 1991; 35(1):51-60. PubMed ID: 1895569
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
11. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
12. Everolimus improves experimental autoimmune uveoretinitis.
Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
Zhang R; Qian J; Guo J; Yuan YF; Xue K
Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
[TBL] [Abstract][Full Text] [Related]
14. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
15. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice.
Avichezer D; Chan CC; Silver PB; Wiggert B; Caspi RR
Exp Eye Res; 2000 Aug; 71(2):111-8. PubMed ID: 10930316
[TBL] [Abstract][Full Text] [Related]
16. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
[TBL] [Abstract][Full Text] [Related]
17. Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype.
Silver PB; Rizzo LV; Chan CC; Donoso LA; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1995 Apr; 36(5):946-54. PubMed ID: 7706044
[TBL] [Abstract][Full Text] [Related]
18. The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice.
Chen J; Vistica B; Wiggert B; Chan CC; Gery I
Ocul Immunol Inflamm; 2005 Feb; 13(1):13-7. PubMed ID: 15804764
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
[TBL] [Abstract][Full Text] [Related]
20. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
